Summit Therapeutics (SMMT) is back in focus after a cluster of ivonescimab milestones, including positive Phase III HARMONi data in The Lancet Oncology, FDA review of its biologics filing, and strong partner results in biliary tract cancer.

The recent ivonescimab milestones sit against a mixed price backdrop for Summit Therapeutics, with the share price up 4.95% on the day and 4.21% over the past week, yet down 23.04% over 90 days and the 1 year total shareholder return declining 50.48%.

Compare Summit Therapeutics with other late stage biotech stories by reviewing hand picked 18 high quality undiscovered gems that are also pushing pivotal clinical pipelines toward key regulatory decisions.

After a sharp rally off the news, yet a 1-year total shareholder return that is still down more than 50%, Summit Therapeutics sits in an awkward middle ground. Has the main ivonescimab upside already been priced in or not?

Most Popular Narrative: 53% Undervalued

At a last close of $13.36 versus a most followed fair value estimate of $28.36, the current pricing for Summit Therapeutics sits well below that narrative anchor and frames the recent rally in a different light.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

Want to see what justifies such a wide gap between today’s price and that fair value line? The narrative leans heavily on rapid revenue build, margin expansion and a future earnings multiple usually reserved for established blockbusters. Curious which assumptions carry the most weight in that story.

Result: Fair Value of $28.36 (UNDERVALUED)

However, the Summit Therapeutics story also hinges on unresolved risks, including the HARMONi FDA decision and the company’s ability to fund heavy R&D without current revenue.

Another View On Summit Therapeutics Valuation

The first fair value story for Summit Therapeutics leans on future earnings and analyst targets. A simple check against today’s pricing using a P/B ratio tells a very different story. SMMT trades at about 16.9x book value, compared with 2.5x for the US Biotechs industry and 10.1x for close peers. That is a wide gap, which can mean more downside risk if expectations cool or a premium that only makes sense if the ivonescimab thesis plays out close to the bullish case. Which narrative feels closer to your own assumptions?

For a closer look at how the numbers stack up using this kind of comparison, review the full valuation breakdown, including where the market could move relative to a fair ratio, in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and concern around Summit Therapeutics feels hard to balance, consider taking action while the details are still fresh. Test the assumptions that matter most to you by reviewing the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Summit Therapeutics?

If you want a broader view than just Summit Therapeutics, use the screener to find other stocks that match your risk appetite and return goals.

Use data to help identify fresh opportunities that might suit your portfolio instead of remaining on the sidelines.

• Explore potential higher growth opportunities early by scanning the 22 elite penny stocks with strong financials that combine smaller market caps with stronger financial characteristics.
• Focus on possible value candidates by reviewing the 49 high quality undervalued stocks that pair healthier balance sheets with pricing that sits below many fair value estimates.
• Consider building a steadier core by focusing on companies in the 74 resilient stocks with low risk scores that our models flag with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.